Last summer, China’s ongoing corruption crackdown found a new target: the healthcare sector.  In an effort to lower medical costs at a time of slowing economic growth, the Chinese government targeted unscrupulous doctors, hospital officials, and pharmaceutical executives. By mid-August, more than 170 hospital administrators were under investigation, according to state media, a dozen Chinese healthcare companies had withdrawn IPO plans, and $142 billion worth of value in Chinese heal